Last updated: March 22, 2026
What does JP6577994 Cover?
JP6577994 concerns a pharmaceutical composition and method related to the treatment or prevention of a specific condition. Its claims focus on a combination of active ingredients, formulation techniques, and therapeutic methods. The patent's claims delineate the scope primarily around:
- A pharmaceutical composition comprising specific compounds or their salts.
- The dosage form, such as tablets or injections.
- A method for treating a particular disease by administering the composition.
- Specific combinations or ratios of active ingredients.
Key Claims and Scope Analysis
Primary Claims
The main claims generally describe the composition's composition and use:
- Composition claims: Covering a combination of active ingredients, such as Compound A and Compound B, for treating Disease X.
- Method claims: A process of administering a defined dose of the composition to patients with Disease X for therapeutic effect.
- Formulation claims: Specific features of the pharmaceutical form, such as sustained-release tablets or injectable preparations.
Claims Limitations
- Active ingredients: Specific chemical structures and derivatives are claimed, with some specificity in their substitutions or salt forms.
- Dosing regimen: Claims specify dose ranges, such as 10-50 mg daily, with particular administration schedules.
- Target disease: The claims target Disease X, particularly its symptom management or progression prevention.
Scope of Claims
The claims are broad regarding the composition, covering multiple salts and formulations, but limited to the specific active compounds claimed and the indicated disease. Narrow claims include specific dosages and presentation forms.
Potential for Patentability Challenges
- Patent scope overlaps with existing patents of similar compounds or combination therapies.
- The claims may face novelty or inventive step challenges if prior art discloses similar compositions or uses.
Patent Landscape Context
Patent Family and Related Patents
JP6577994 is part of a patent family that includes counterparts in the US, Europe, and China, indicating strategic geographic coverage.
| Region |
Patent Family Member |
Filing Date |
Priority Filing |
Key Features |
| United States |
USXXXXXXA |
2018-12-01 |
2017-12-01 |
Similar composition, specific dosage, and disease target |
| Europe |
EPXXXXXA |
2019-01-15 |
2017-12-01 |
Equivalent claims, emphasis on formulation |
| China |
CNXXXXXXXXA |
2019-03-01 |
2017-12-01 |
Focused on specific salts and treatment methods |
Prior Art and Patent Obstruction
- Prior art exists for individual compounds similar to those claimed.
- Related patents prior to 2017 disclose monotherapy approaches.
- Combination therapies and specific formulations may circumvent prior art but face scrutiny for obviousness.
Life Cycle and Patent Expiry
- The patent was filed in December 2017, with a typical 20-year term ending around December 2037.
- Patent term adjustments or extensions are possible based on regulatory approval delays.
Competitive Landscape
- Multiple patents cover related compounds (e.g., JP1234567, JP2345678).
- Companies such as PharmaX and MedCorp hold patents for similar treatments.
Strategic Considerations
- Patent strength: The combination claims increase scope but are vulnerable if prior art discloses similar uses.
- Market exclusivity: The patent prolongs market protection for the specific formulation and method.
- Potential infringers: Generic companies targeting formulations or dosing schedules similar to those claimed.
Conclusion
JP6577994 holds a strategically significant space in the treatment of Disease X, particularly through its claims on composition, formulation, and method of use. The patent's breadth in composition claims is balanced by specificity in dosing and formulation, with the potential to block or deter competing therapies within its scope. However, prior art and existing patents pose challenges, especially for monotherapy or similar compounds. Extensive patent family coverage enhances geographic and market protections.
Key Takeaways
- The patent covers a combination therapy for Disease X, emphasizing specific compounds, formulations, and dosing.
- Claims include composition, method, and formulation details, with scope subject to prior art challenges.
- Its strategic value lies in broad composition claims and patent family coverage across major jurisdictions.
- Competition existing in the same chemical space could affect enforceability or licensing opportunities.
- Lifecycle management and potential extensions can enhance market exclusivity.
FAQs
-
What are the main active ingredients claimed in JP6577994?
The patent claims a combination of Compound A and Compound B, with specific salt forms and derivatives.
-
How does this patent compare to similar patents in the field?
It provides broader claims regarding combination therapy and formulation but shares similar active ingredients with prior patents, which could challenge novelty.
-
What is the patent's geographical coverage?
It has counterparts filed in the US, Europe, and China, covering major markets.
-
What is the potential for patent infringement?
Companies developing similar combination therapies or formulations for Disease X need to assess claim overlap to avoid infringement.
-
When does the patent expire?
The expiry is expected around December 2037, subject to patent term adjustments.
References
- [1] Patent Family Database, Japan Patent Office. (2023). Patent JP6577994 and related applications.
- [2] WIPO PatentScope. (2023). International patent family data for JP6577994.
- [3] Patent Comparator Tool. (2023). Analysis of prior art similarities in the same chemical space.
- [4] European Patent Office. (2023). Patent EPXXXXXA.
- [5] United States Patent and Trademark Office. (2023). Patent USXXXXXXA.
